

# Major Advance in Intestinal Health

## References

1. Kazmierczak Z, Gorski A, Dabrowska K. Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool. *Viruses*. 2014;6(7):2551-70.
2. Dalmasso M, de Haas E, Neve H, et al. Isolation of a Novel Phage with Activity against Streptococcus mutans Biofilms. *PLoS One*. 2015;10(9):e0138651.
3. Chibeu A, Lingohr EJ, Masson L, et al. Bacteriophages with the ability to degrade uropathogenic Escherichia coli biofilms. *Viruses*. 2012;4(4):471-87.
4. Bruynoghe R, and J. Maisin. Essais de thérapeutique au moyen du bacteriophage. *C. R. Soc. Biol.* . 1921;85:1120-1.
5. Abedon ST, Kuhl SJ, Blasdel BG, et al. Phage treatment of human infections. *Bacteriophage*. 2011;1(2):66-85.
6. Pelfrene E, Willebrand E, Cavaleiro Sanches A, et al. Bacteriophage therapy: a regulatory perspective. *Journal of Antimicrobial Chemotherapy*. 2016;71(8):2071-4.
7. Fortuna W, Miedzybrodzki R, Weber-Dabrowska B, et al. Bacteriophage therapy in children: facts and prospects. *Med Sci Monit*. 2008;14(8):RA126-32.
8. Dabrowska K, Switala-Jelen K, Opolski A, et al. Bacteriophage penetration in vertebrates. *J Appl Microbiol*. 2005;98(1):7-13.
9. Ashelford KE, Day MJ, Fry JC. Elevated abundance of bacteriophage infecting bacteria in soil. *Appl Environ Microbiol*. 2003;69(1):285-9.
10. Sillankorva SM, Oliveira H, Azeredo J. Bacteriophages and their role in food safety. *Int J Microbiol*. 2012;2012:863945.
11. Woolston J, Parks AR, Abuladze T, et al. Bacteriophages lytic for Salmonella rapidly reduce Salmonella contamination on glass and stainless steel surfaces. *Bacteriophage*. 2013;3(3):e25697.
12. Garcia P, Martinez B, Obeso JM, et al. Bacteriophages and their application in food safety. *Lett Appl Microbiol*. 2008;47(6):479-85.
13. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. *Future Microbiol*. 2013;8(6):769-83.
14. Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. *Mayo Clin Proc*. 2014;89(1):107-14.
15. Van den Abbeele P, Verstraete W, El Aidy S, et al. Prebiotics, faecal transplants and microbial network units to stimulate biodiversity of the human gut microbiome. *Microb Biotechnol*. 2013;6(4):335-40.
16. Brown K, DeCoffe D, Molcan E, et al. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. *Nutrients*. 2012;4(8):1095-119.
17. Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. *Gastroenterology*. 2012;142(5):1100-1 e2.
18. Watkins RR, Bonomo RA. Overview: Global and Local Impact of Antibiotic Resistance. *Infect Dis Clin North Am*. 2016;30(2):313-22.
19. Francino MP. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. *Front Microbiol*. 2015;6:1543.
20. Carding S, Verbeke K, Vipond DT, et al. Dysbiosis of the gut microbiota in disease. *Microbial Ecology in Health and Disease*. 2015;26:10.3402/mehd.v26.26191.
21. Daulatzai MA. Role of stress, depression, and aging in cognitive decline and Alzheimer's disease. *Curr Top Behav Neurosci*. 2014;18:265-96.
22. Sun J, Chang EB. Exploring gut microbes in human health and disease: Pushing the envelope. *Genes & Diseases*. 2014;1(2):132-9.
23. Saraswati S, Sitaraman R. Aging and the human gut microbiota-from correlation to causality. *Front Microbiol*. 2014;5:764.
24. Magrone T, Jirillo E. The interaction between gut microbiota and age-related changes in immune function and inflammation. *Immun Ageing*. 2013;10(1):31.

25. Woodmansey EJ. Intestinal bacteria and ageing. *J Appl Microbiol.* 2007;102(5):1178-86.
26. Hopkins M, Sharp R, Macfarlane G. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. *Gut.* 2001;48(2):198-205.
27. Galland L. The gut microbiome and the brain. *J Med Food.* 2014;17(12):1261-72.
28. Giloteaux L, Goodrich JK, Walters WA, et al. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. *Microbiome.* 2016;4(1):30.
29. Jackson ML, Butt H, Ball M, et al. Sleep quality and the treatment of intestinal microbiota imbalance in Chronic Fatigue Syndrome: A pilot study. *Sleep Sci.* 2015;8(3):124-33.
30. Navaneetharaja N, Griffiths V, Wileman T, et al. A Role for the Intestinal Microbiota and Virome in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)? *J Clin Med.* 2016;5(6).
31. Shukla SK, Cook D, Meyer J, et al. Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). *PLoS One.* 2015;10(12):e0145453.
32. Elphick HL, Elphick DA, Sanders DS. Small bowel bacterial overgrowth. An underrecognized cause of malnutrition in older adults. *Geriatrics.* 2006;61(9):21-6.
33. Khalighi AR, Khalighi MR, Behdani R, et al. Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth (SIBO)--a pilot study. *Indian J Med Res.* 2014;140(5):604-8.
34. Dharmarajan TS, Pitchumoni CS. Small Intestinal Bacterial Overgrowth Syndrome. In: Pitchumoni SC, Dharmarajan ST, eds. *Geriatric Gastroenterology.* New York, NY: Springer New York; 2012:457-62.
35. Zhang Y-J, Li S, Gan R-Y, et al. Impacts of Gut Bacteria on Human Health and Diseases. *International Journal of Molecular Sciences.* 2015;16(4):7493-519.
36. Conlon MA, Bird AR. The Impact of Diet and Lifestyle on Gut Microbiota and Human Health. *Nutrients.* 2015;7(1):17-44.
37. Mimee M, Citorik RJ, Lu TK. Microbiome therapeutics - Advances and challenges. *Adv Drug Deliv Rev.* 2016.
38. Allen KP, Randolph MM, Fleckenstein JM. Importance of heat-labile enterotoxin in colonization of the adult mouse small intestine by human enterotoxigenic Escherichia coli strains. *Infect Immun.* 2006;74(2):869-75.
39. Coster TS, Wolf MK, Hall ER, et al. Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli. *Infect Immun.* 2007;75(1):252-9.
40. Supplier Internal Study. A Probiotic-Enhancing Prebiotic. Data on File. 2016.
41. Supplier Internal Study. Bacteriophage Cocktail Mice Clinical Trials. Data on File. 2016.
42. Alisky J, Iczkowski K, Rapoport A, et al. Bacteriophages show promise as antimicrobial agents. *J Infect.* 1998;36(1):5-15.
43. Sarker SA, McCallin S, Barretto C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. *Virology.* 2012;434(2):222-32.
44. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. *Antimicrob Agents Chemother.* 2005;49(7):2874-8.
45. McCallin S, Alam Sarker S, Barretto C, et al. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. *Virology.* 2013;443(2):187-96.
46. Meader E, Mayer MJ, Gasson MJ, et al. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. *Anaerobe.* 2010;16(6):549-54.